Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis

Oscar Cirioni, Carmela Silvestri, Roberto Ghiselli, Fiorenza Orlando, Alessandra Riva, Eleonora Gabrielli, Federico Mocchegiani, Nancy Cianforlini, Maria Michela Cappelletti Trombettoni, Vittorio Saba, Giorgio Scalise, Andrea Giacometti

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To investigate the efficacy of buforin II and rifampin in an experimental rat model of Acinetobacter baumannii sepsis. DESIGN: Prospective, randomized, controlled animal study. SETTING: Research laboratory in a university hospital. SUBJECTS: Adult male Wistar rats. INTERVENTIONS: The animals received intraperitoneally 1 mL saline containing 2 × 10 colony forming units of A. baumannii ATCC 19606 (model i) or the multiresistant strain (model ii). Immediately after bacterial challenge, animals received intravenously a single dose of isotonic sodium chloride solution (control groups C1 and C2), 1 mg/kg of buforin II, 10 mg/kg of rifampin, and 1 mg/kg of buforin II plus 10 mg/kg of rifampin, respectively. MEASUREMENTS AND MAIN RESULTS: Lethality, bacterial growth in blood and tissue burden, endotoxin, interleukin-6, and tumor necrosis factor-α concentrations in plasma. Buforin II showed good antimicrobial activity and achieved a significant reduction of plasma endotoxin and cytokines concentration when compared with control and rifampin-treated groups. Combination among buforin II proved to be the most effective treatment in reducing all variables measured. CONCLUSION: In an experimental model, buforin II and rifampin might have a potential role in the treatment of severe infections due to A. baumannii.

Original languageEnglish
Pages (from-to)1403-1407
Number of pages5
JournalCritical Care Medicine
Issue number4
Publication statusPublished - Apr 2009


  • A. baumannii
  • Animal model
  • Antimicrobial peptides
  • Multiresistant organisms
  • Sepsis
  • Synergy

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis'. Together they form a unique fingerprint.

Cite this